Research programme: substance P analogues - New Amsterdam Sciences

Drug Profile

Research programme: substance P analogues - New Amsterdam Sciences

Alternative Names: NAS-911; NAS-911B; NAS-911C; NAS-911DFU; NAS-911F; NAS-911PF; Neurokinin-1 receptor agonists - New Amsterdam Sciences

Latest Information Update: 12 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New Amsterdam Sciences
  • Developer National Institutes of Health (USA); New Amsterdam Sciences
  • Class Peptides
  • Mechanism of Action Immunostimulants; Neurokinin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute radiation syndrome; Cancer; Diabetic foot ulcer; Idiopathic pulmonary fibrosis; Influenza virus infections

Most Recent Events

  • 09 Aug 2014 New Amsterdam Sciences' substance P analogues programme is available for licensing as of 09 Aug 2014.
  • 06 Aug 2014 Preclinical trials in Acute radiation syndrome in USA (PO)
  • 06 Aug 2014 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top